GMAB - Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript
2024-02-14 16:17:11 ET
Genmab A/S (GMAB)
Q4 2023 Results Conference Call
February 14, 2024 12:00 PM ET
Company Participants
Jan van de Winkel - Co-Founder, President and Chief Executive Officer
Anthony Mancini - Executive Vice President & COO
Anthony Pagano - Executive Vice President & CFO
Tahi Ahmadi Genmab - Executive VP, Chief Medical Officer
Conference Call Participants
James Gordon - JPMorgan Chase & Co
Kaveri Pohlman - BTIG
Peter Verdult - Citigroup Inc
Sachin Jain - BofA Securities
Jonathan Chang - Leerink
Paul Jeng - Guggenheim Securities
Peter Welford - Jefferies
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Genmab Full Year 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode. After the speakers' presentation, there will be the question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded.
This presentation contains forward-looking statements. The words believe, expect, anticipate, intent, and plan, and similar expressions identify forward-looking statements. All statements other than statements of historical facts included in this presentation, including without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations, including development plans and objectives relating to our products, are forward-looking statements.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward-looking statement includes, among other, risks associated with products discovery and development, uncertainties related to the outcome of clinical trials, slower-than-expected rate of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and the markets, our inability to attract and retain suitably qualified personnel, the enforceability or lack of protection of our patents or proprietary rights, our relationships with affiliated entities, changes and developments in technology, which may render our products obsolete, and other factors.
Further, certain forward-looking statements are based upon assumptions of future events, which may not prove to be accurate. The forward-looking statements in these documents speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward-looking statements in this presentation, nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
At this moment, I would like to hand the conference over to our first speaker today, Jan van de Winkel. Please go ahead....
Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript